Ginger-PD: Ginger as a Modifier of Ghrelin Levels and Gut Function in Parkinson's Disease
NCT07882108 · REM Sleep Behavior Disorder, Parkinson s Disease
RecruitingThis study will test whether taking ginger supplements can increase ghrelin, a hunger hormone that is decreased in the blood of people with Parkinson's disease (PD) and REM Sleep Behaviour disorder (RBD). Three groups of participants are taking part: 1. People with Parkinson's disease (PD); 2. People with REM Sleep Behaviour Disorder (RBD); 3. Healthy people of similar age and sex. The investigators aim to include 24 participants per group. Each participant will take ginger capsules for 12 weeks at one of two dose levels (0.24g or 0.48g of ginger root extract supplement) allocated at random. The main goal is to find out whether ginger causes a dose-related increase in blood ghrelin levels. Secondary goals are to explore whether ginger: 1. reduces levels of inflammation in the blood 2. improves gut symptoms including constipation 3. is well tolerabled in people with Parkinons's If the study shows that ginger increases ghrelin levels, it will provide important early evidence to support a future larger clinical trial to determine whether ginger supplements could help slow or modify Parkinson's disease by increasing blood ghrelin levels.
PhaseNA
TypeInterventional
Age55 Years
WhereCambridge, United Kingdom
SponsorCambridge University Hospitals NHS Foundation Trust
▾Tap for detailsClick for full details — eligibility, all locations, contacts Interest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life
RecruitingCare for Parkinson's patients at the end of life is far from optimal, particularly due to specificities linked to the disease itself, often unknown to non-specialists. A study carried out at the CHU Rennes on data covering the period 2006-2018 showed that only 132 patients died in this hospital, two-thirds of whom came from home. In 42% of cases, antiparkinsonian treatment was stopped before death without specialist advice (palliative or neurological), with the corollary of the appearance of a dopaminergic withdrawal syndrome (or pseudo-neuroleptic malignant syndrome) in a high proportion of these patients. Neuroleptic pseudo-malignant syndrome is a major cause of discomfort. If left untreated, it can precipitate death in particularly distressing conditions for the patient, his or her family and caregivers. The Rennes study also suggests that Parkinson's patients rarely die in hospital. In fact, work carried out by FNEHAD on data for 2022 showed that 1,800 Parkinson's patients were cared for in HAH in France during that same year, mainly for palliative care or heavy nursing reasons. Half of these patients died. End-of-life management of Parkinson's disease therefore requires local clinical and pharmacological expertise. A recent observational study suggests that the use of a subcutaneous apomorphine pump brings substantial benefits in terms of clinical comfort, both motor and non-motor, as well as relief for family and friends, easier nursing care for the nursing team, and in some cases, renewed communication. Such care can be provided in the home, and must necessarily be multidisciplinary, combining palliative expertise, provided by Home Hospitalization (HH) teams, with technical and Parkinson's expertise, provided by Home Healthcare Providers (HHPs) experienced in managing the apomorphine pump, in liaison with the referral team.
Phase—
TypeObservational
Age18 Years
WhereCrest, France
SponsorCentre Hospitalier Régional d'Orléans
▾Tap for detailsClick for full details — eligibility, all locations, contacts Insulin Resistance in Multiple System Atrophy
NCT04250493 · Multiple System Atrophy
RecruitingMultiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder. The pathologic hallmark is the accumulation of aggregated alpha-synuclein in oligodendrocytes forming glial cytoplasmic inclusions. Some symptomatic treatments are available while disease-modification remains an unmet treatment need. Post-mortem findings suggest insulin resistance, i.e. reduced insulin signaling, in the brains of MSA patients. The aim of this study is to complete the target validation of insulin resistance for future treatment trials.
PhaseNA
TypeInterventional
Age30 Years
WhereBordeaux, France
SponsorUniversity Hospital, Bordeaux
▾Tap for detailsClick for full details — eligibility, all locations, contacts SegwayPD: The Effect of Sensory-augmented Postural Training Using Segway on Motor and Cognitive Function in Individuals With Parkinson's Disease
RecruitingThe purpose of this study is to examine the safety and efficacy of postural training emphasized on the integration of multiple sensory information into motor control in individuals with PD. This project is a proof-of-concept study to assess the effectiveness of postural training using Segway, which serves a platform to provide augmented and continuous proprioceptive and visuospatial information during postural training.
PhaseNA
TypeInterventional
Age50 Years – 85 Years
WhereDallas, Texas, United States
SponsorUniversity of Texas Southwestern Medical Center
▾Tap for detailsClick for full details — eligibility, all locations, contacts Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)
RecruitingThis project will explore the involvement of the serotonin system in the pathophysiology of PD-related central pain. Thus, the serotonin system will be evaluated in PD patients with and without central pain who will benefit from brain positron emission tomography (PET) allowing in vivo imaging of 5HT1A receptors and multimodal brain MRI including morphometric imaging and functional connectivity (resting state acquisition).
PhaseNA
TypeInterventional
Age40 Years – 80 Years
WhereToulouse, Haute-Garonne, France
SponsorUniversity Hospital, Toulouse
▾Tap for detailsClick for full details — eligibility, all locations, contacts Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RecruitingThis first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab, docetaxel, carboplatin, paclitaxel, osimertinib, anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), rearranged during transfection (RET) TKIs, BNT316 (an anti-cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\] antibody), an anti-B7-H3 antibody conjugated to a topoisomerase I inhibitor, an anti-human epidermal growth factor receptor 3 (HER3) antibody conjugated to a topoisomerase I inhibitor or a bispecific antibody for programmed death ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A) in participants with non-small cell lung cancer (NSCLC). The study will comprise several cohorts for dose confirmation in monotherapy as well as in combinations of BNT116 as mentioned above. The study will enroll participants with NSCLC in advanced or metastatic stage in Cohorts 1 to 4 and Cohorts 7 to 10, unresectable NSCLC Stage III in Cohorts 5 and 11, resectable NSCLC of Stage II and III in Cohort 6, advanced/metastatic epidermal growth factor receptor (EGFR)-mutant NSCLC in Cohort EGFR, and advanced/metastatic ALK rearranged or RET rearranged NSCLC in Cohort ALK/RET. Cohort EGFR and Cohort ALK/RET will enroll only at selected sites in the US.
PhasePhase 1
TypeInterventional
Age18 Years
WhereLexington, Kentucky, United States + 44 more
SponsorBioNTech SE
▾Tap for detailsClick for full details — eligibility, all locations, contacts Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease
RecruitingThis trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo. Along with the study medication participants will have visits (over the phone and in person), various tests and imaging, questionnaires, and laboratory collections.
PhasePhase 2
TypeInterventional
Age45 Years
WhereAnn Arbor, Michigan, United States
SponsorVikas Kotagal
▾Tap for detailsClick for full details — eligibility, all locations, contacts PARKINSON BRASIL - Database on Motor and Non-Motor Aspects of Parkinson's Disease in Brazil
RecruitingThis is an observational, cross-sectional study with a control group, with the general objective of developing and evaluating a national database, unprecedented in Brazil, containing clinical, epidemiological, motor, and non-motor aspects of Parkinson's disease (PD). The database will be open and accessible to national and international researchers in order to contribute to the advancement of research related to PD. The aim is to collect data, in a paired way, from a control group and an experimental group. Data collection will include the application of questionnaires, the execution of motor activities, and clinical scales. Information that can identify the participants will be removed from the database for later storage in a repository. Quantitative, qualitative, and descriptive variables from the database will be estimated in order to characterise and contrast the groups studied. The results of this study will contribute to a better characterization of the staging of PD as a function of the epidemiological, motor, and non-motor aspects evaluated, as well as to the development of technologies and methods that can be applied in clinical practice.
Phase—
TypeObservational
Age18 Years – 120 Years
WhereBrasília, Federal District, Brazil + 4 more
SponsorFederal University of Uberlandia
▾Tap for detailsClick for full details — eligibility, all locations, contacts Research on Novel Biomarkers for Early Diagnosis of Parkinson's Disease:An Observational, Multicenter, Non-Randomized Controlled Study
RecruitingThis observational, multicenter, non-randomized controlled study is to evaluate the detection ability of α-Synuclein Ultrafine Fluorescence Detection Method for body fluids (Such as saliva, urine, cerebrospinal fluid, and blood, etc.) and skin in Parkinson's patients.
Phase—
TypeObservational
Age18 Years – 80 Years
WhereNanning, Guangxi, China
SponsorYousheng Xiao
▾Tap for detailsClick for full details — eligibility, all locations, contacts Cognitive-motor Training in Parkinson Disease
RecruitingLiterature reviews showed the cognitive-motor training that combines cognitive tasks may enhance cognitive functions more effectively than individual interventions. Stepping-based cognitive-motor training has been shown to improve cognitive functions, balance, and gait performance in older adults. However, there is insufficient research evidence on the impact and correlation of this training mode on the walking ability, executive functions, and brain activity changes in people with PD. Therefore, this study is designed to investigate the effects of stepping-based cognitive-motor training on the walking ability, executive functions, and brain activity in people with PD.
PhaseNA
TypeInterventional
Age40 Years – 80 Years
WhereTaipei, Taiwan
SponsorNational Yang Ming Chiao Tung University
▾Tap for detailsClick for full details — eligibility, all locations, contacts Robotic Apparel to Prevent Freezing of Gait in Parkinson Disease
RecruitingFreezing-of-gait (FoG) in Parkinson Disease (PD) is one of the most vivid and disturbing gait phenomena in neurology. Often described by patients as a feeling of "feet getting glued to the floor," FoG is formally defined as a "brief, episodic absence or marked reduction of forward progression of the feet despite the intention to walk." This debilitating gait phenomena is very common in PD, occurring in up to 80% of individuals with severe PD. When FoG arrests walking, serious consequences can occur such as loss of balance, falls, injurious events, consequent fear of falling, and increased hospitalization. Wearable robots are capable of augmenting spatiotemporal gait mechanics and are emerging as viable solutions for locomotor assistance in various neurological populations. For the proposed study, our goal is to understand how low force mechanical assistance from soft robotic apparel can best mitigate gait decline preceding a freezing episode and subsequent onset of FoG by improving spatial (e.g. stride length) and temporal features (e.g. stride time variability) of walking. We hypothesize that the ongoing gait-preserving effects can essentially minimize the accumulation of motor errors that lead to FoG. Importantly, the autonomous assistance provided by the wearable robot circumvents the need for cognitive or attentional resources, thereby minimizing risks for overloading the cognitive systems -- a known trigger for FoG, thus enhancing the repeatability and robustness of FoG-preventing effects.
PhaseNA
TypeInterventional
Age18 Years – 90 Years
WhereAllston, Massachusetts, United States + 1 more
SponsorHarvard Medical School (HMS and HSDM)
▾Tap for detailsClick for full details — eligibility, all locations, contacts DBS and Levodopa for Treating Freezing of Gait in Parkinson's Disease
NCT06316232 · Freezing of Gait,
Parkinson Disease RecruitingFreezing of gait (FoG) is a complex symptom of Parkinson's disease (PD) that cause falls and disability in PD patients, heavily affect patients' autonomy and quality of life. Gait disturbances and FoG are difficult to manage as they usually do not complete respond to both dopaminergic treatment and subthalamic nucleus deep brain stimulation (STN-DBS). One therapeutic strategy suggested in literature for improving gait disturbances is to increase the dose of dopaminergic drugs according to the hypothesis of pseudo-ON-freezing. The pseudo-ON-FoG in patients treated with STN-DBS can easily occur as the result of a suboptimal stimulation or the consequence of a post-operative reduction of the dopaminergic therapy. Therefore, it is reasonable hypothesize both the increase of stimulation and levodopa as good therapeutic strategies to improve pseudo-ON-FoG. At present there are no evidence for suppose that one option is better than the other, even though two recent studies on gait analysis reported a positive additive effect of levodopa therapy on gait parameters in patients treated with STN-DBS. In this study, the investigators aim to objectively evaluating the improvement of FoG in PD patients treated with STN-DBS at different treatment conditions consisting of increased intensity of stimulation or higher dosage of levodopa.
PhasePhase 4
TypeInterventional
Age18 Years – 80 Years
WhereBologna, Italy
SponsorIRCCS Istituto delle Scienze Neurologiche di Bologna
▾Tap for detailsClick for full details — eligibility, all locations, contacts Minimal Clinically Important Difference of the Box and Block Test in Parkinson
RecruitingThe aim of this study is to examine the level of clinical change in gross manual skills of Parkinson's patients who receive conventional physiotherapy. For this purpose, the Box-Block Test will be used, and the amount of change that must occur in the patient's hand functions will be determined for the test to be considered clinically meaningful. Patients will continue their routine physical therapy sessions and the researchers will not interfere with this program. The treatment program will be created by the clinical specialist physician and physiotherapist. Upper extremity rehabilitation programs for Parkinson's patients generally consist of methods such as stretching, strengthening, reaching, coordination and recreational activities. Patients will receive physiotherapy for 30 sessions.
PhaseNA
TypeInterventional
Age50 Years – 80 Years
WhereIstanbul, Turkey (Türkiye)
SponsorEmre Şenocak
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA
NCT07604116 · Multiple System Atrophy (MSA),
Parkinson's Disease (PD) RecruitingThe non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.
PhasePhase 1
TypeInterventional
Age18 Years
WhereWuxi, Jiangsu, China + 1 more
SponsorSynusight Biotech (Shanghai) Co., Ltd.
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
RecruitingThe main goal of the study is to investigate how well the new drug SUL-238 works in Parkinson's Disease (PD). This is done by means of an MRS scan. An MRS scan is similar to a regular MRI scan. It will also learn about the safety of new drug SUL-238. The main questions it aims to answer are: * Does new drug SUL-238 improve the mitochondrial function in patients with Parkinson's Disease (PD)? * What medical problems do participants have when taking new drug SUL-238? Researchers will compare new drug SUL-238 to a placebo (a look-alike substance that contains no drug) to see if SUL-238 works to improve mitochondrial function in patients with PD. Participants will: * Take new drug SUL-238 or a placebo every day for 28 days * Visit the clinic once every 2 weeks for checkups and tests during the treatment period and finally 28 days after the last dose of SUL-238 * Keep a diary of their symptoms and the number of times they use oral new drug SUL-238
PhasePhase 2
TypeInterventional
Age40 Years
WhereGroningen, Netherlands
SponsorGEN İlaç ve Sağlık Ürünleri A.Ş.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Alleviate Locomotor Deficits in People With Parkinson's Disease
RecruitingThe purpose of this clinical trial is to assess the preliminary safety and efficacy of the ARC-IM spinal cord stimulation therapy in alleviating locomotor deficits in individuals with Parkinson's disease. The ARC-IM Therapy employs epidural electrical stimulation (EES) to modulate leg muscle recruitment, with the aim of improving mobility deficits. The ultimate goal is to enhance the quality of life of people with Parkinson's disease.
PhaseNA
TypeInterventional
Age18 Years
WhereLausanne, Canton of Vaud, Switzerland
SponsorEcole Polytechnique Fédérale de Lausanne
▾Tap for detailsClick for full details — eligibility, all locations, contacts AV133 Longitudinal Imaging Study in Patients With Early and Prdromal Parkinson's Disease
RecruitingA total of 38 patients with early-stage Parkinson's disease and 38 patients with prodromal Parkinson's disease are planned to be enrolled in this study and examined for longitudinal changes in \[18F\]AV-133 through follow-up, thereby informing the design of future therapeutic trials utilizing \[18F\]AV-133 as a marker of disease progression.
Phase—
TypeObservational
Age30 Years
WhereBeijing, Beijing Municipality, China
SponsorXuanwu Hospital, Beijing
▾Tap for detailsClick for full details — eligibility, all locations, contacts A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
RecruitingThis is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 14 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given. The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and a 12-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.
PhasePhase 2
TypeInterventional
Age30 Years – 80 Years
WhereLittle Rock, Arkansas, United States + 29 more
SponsorAppello Pharmaceuticals, Inc.
▾Tap for detailsClick for full details — eligibility, all locations, contacts Vinpocetine in Patients With Parkinsonian Disease
RecruitingThe clinical manifestations of Parkinson's disease (PD), a chronic neurodegenerative condition, include resting tremor, hypokinesia, bradykinesia, stiffness and postural instability. These motor symptoms are caused by a selective loss and degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) region, which leads to a dopamine (DA) insufficiency in the striatum
PhasePhase 2 / Phase 3
TypeInterventional
Age50 Years – 70 Years
WhereTanta, Egypt
SponsorTanta University
▾Tap for detailsClick for full details — eligibility, all locations, contacts Wearable for Assessing Tremor and Continuous Health in Parkinson's Disease and Essential Tremor
RecruitingThis prospective observational study will examine tremor and upper-limb movement in adults with Parkinson's disease or essential tremor using non-invasive wearable sensors. Participants will attend one clinic visit and may then wear sensors at home for 3, 7, or 21 days. Clinic assessments will be scheduled around participants' usual medication times; the study will not change or delay treatment. Sensor data will be analysed offline for research and will not be used to make clinical decisions.
Phase—
TypeObservational
Age18 Years
WhereEdinburgh, Edinburgh, United Kingdom
SponsorHeriot-Watt University
▾Tap for detailsClick for full details — eligibility, all locations, contacts